wegovy novo nordisk - Search News

The Motley Fool on MSN · 1d

Why Novo Nordisk Stock Keeps Going Down

Novo Nordisk ( NVO -2.98%) stock is in a funk. Shares of the GLP-1 diet drug manufacturer have been sliding all week long, beginning with a 3% decline on Monday from last Friday's close, and falling another 2.6% through 10:10 a.m. ET on Thursday.

Seeking Alpha · 1d

Novo Nordisk: Dips Like These Come Once Every Few Years

Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy with promising growth in obesity care.

Wall Street Journal · 9d

Novo Nordisk Earnings Boost Stock in Ozempic Maker

Novo Nordisk stock gained, lifted by strong sales growth and guidance from the maker of Wegovy and Ozempic. Shares in Novo, one of Europe's largest listed companies, advanced nearly 3% in Denmark. Dig

Investing.com on MSN · 2d

Bernstein raises Novo Nordisk stock target to DKK620

Bernstein analysts led by Florent Cespedes increased their price target on Novo Nordisk (NOVOB:DC) (NYSE: NYSE:NVO) stock to DKK620.00, up from DKK600.00, while maintaining a Market Perform rating. The $365 billion market cap company,

2hon MSN

Novo Nordisk stock is having a rough week after that Hims & Hers Super Bowl ad

Novo Nordisk (NVO) stock took a hit this week, after a Super Bowl ad highlighted a growing challenge to the company’s ...

The Motley Fool on MSN12d

Forget Wegovy: Novo Nordisk May Have a New Billion-Dollar Weight Loss Drug On Its Hands

In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...

9d

Wegovy sales double to boost Novo Nordisk's fourth quarter as growth set to slow

Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the fourth quarter, ...

9don MSN

Novo Nordisk beats on Wegovy sales, expects slower 2025 growth

Danish drugmaker Novo Nordisk reported fourth quarter and full year 2024 earnings Wednesday, beating Wall Street's ...

Modern Healthcare4d

Ozempic, Wegovy maker responds to Hims & Hers Super Bowl ad

Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.

Wegovy maker Novo Nordisk says surging growth driving emissions higher

LONDON/COPENHAGEN, Feb 5 (Reuters) - Novo Nordisk emissions grew 23% in 2024, the company said on Wednesday, and will ...

3d

Ozempic, Wegovy maker calls out Hims & Hers Super Bowl ad: ‘Check before you inject’

Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and ...

8don MSN

Novo Nordisk Outlook Provides Some Welcome Relief

The Danish pharmaceutical company’s blockbuster Wegovy weight-loss drug just missed sales expectations in the fourth quarter ...

9don MSN

As growth slows, CFO says Novo Nordisk is prepping for the next generation of weight loss drugs

Novo’s newest GLP-1, CagriSema, is the first big test of Novo Nordisk’s future as the leader in the obesity treatment market.

Lilly, Novo Skew Overall Pharma Trends With Colossal GLP-1 Sales Growth

From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results